The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sequential administration of high-dose interleukin-2 and ipilimumab in patients with metastatic melanoma.
 
Sapna Pradyuman Patel
Stock and Other Ownership Interests - Provectus
Honoraria - Dava Oncology; PCME, Rockpointe; PlatformQ Health
Consulting or Advisory Role - Amgen; Genentech/Roche
Speakers' Bureau - Bristol-Myers Squibb (Mexico); Merck
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Prometheus (Inst); Reata Pharmaceuticals (Inst)
 
Denai Milton
No Relationships to Disclose
 
Mohammed M. Milhem
Honoraria - Amgen; EMD Serono
Consulting or Advisory Role - Amgen; EMD Serono
Travel, Accommodations, Expenses - Amgen; EMD Serono
 
Lawrence E. Flaherty
Consulting or Advisory Role - Caris Life Sciences; Merck/Schering Plough
Travel, Accommodations, Expenses - Caris Life Sciences; Merck/Schering Plough
 
Sigrun Hallmeyer
Consulting or Advisory Role - Cardinal Health
Speakers' Bureau - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Cardinal Health
 
Lynn G. Feun
No Relationships to Disclose
 
Ralph J. Hauke
Stock and Other Ownership Interests - Aethlon
Honoraria - Best Doctors, Inc
Research Funding - Amgen (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); US Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending on an immunotherapeutic
Other Relationship - ABIM Subspecialty Board
 
Lee D. Cranmer
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche; Merck
Research Funding - Amgen; Bristol-Myers Squibb; CytRx Corporation; GlaxoSmithKline; Merck; Prometheus; Threshold Pharmaceuticals
 
Gregory A. Daniels
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Prometheus (Inst); Viralytics (Inst)
 
Gary C. Doolittle
Consulting or Advisory Role - Amgen; Genentech
Speakers' Bureau - Merck Sharp & Dohme; Prometheus
 
Bret Taback
No Relationships to Disclose
 
Michael Morse
Stock and Other Ownership Interests - PhytoChem
Honoraria - Astellas Pharma; Bayer; Boehringer Ingelheim; EMD Serono; Etubics; Genentech/Roche; Ipsen; Lexicon; Merrimack; Novartis; Onyx; Regeneron; Sanofi; Taiho Pharmaceutical
Speakers' Bureau - Celgene; Genentech/Roche; Novartis
Research Funding - Advanced Accelerator Applications (Inst); AlphaVax (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lexicon (Inst); MedImmune (Inst); Onyx (Inst); Precision Biologics (Inst)
 
Jose Lutzky
Honoraria - Bristol-Myers Squibb; Genentech/Roche
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche
Research Funding - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Merck; Merck Serono; Millennium; Novartis; Onconova Therapeutics; Prometheus; Viralytics
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Prometheus
 
William Howard Sharfman
Consulting or Advisory Role - Merck
Research Funding - Bristol-Myers Squibb (Inst)